Objective: The aim of this study was to examine the relationship between self-reported estrogen use and newly incident urinary incontinence (UI) among community-dwelling postmenopausal women.
U rinary incontinence (UI) is common in women and may be disabling. The incidence of UI increases with age and after menopause. 1 Emerging evidence suggests that postmenopausal hormone therapy is associated with an increased risk of UI, 2<7 although the biological mechanisms for this increased risk are unclear. Previous randomized controlled trials have indicated that the use of hormone therapy worsens UI symptoms or increases the risk of developing UI. 2, 3, 5 Results from the Women's Health Initiative demonstrated that postmenopausal women randomized to receive either estrogen plus progestin or estrogen only were at increased risk of experiencing worsening UI symptoms or developing incident UI after 1 year. 5 These findings were observed for both stress and urge UI. Other observational studies showed a relationship between the current use of postmenopausal hormone therapy and incident UI during follow-up. 6, 7 However, many of the studies examining the use of hormone therapy and UI were conducted in largely homogeneous populations with few comorbid health conditions or selected comorbid health conditions, thus limiting the generalizability of the findings.
Despite the presence of evidence linking postmenopausal hormone therapy to the risk of developing UI, it remains important to further delineate the characteristics of women at highest risk of developing UI leading to a loss in functioning, which may limit both social and physical activities. To that end, the role of hormone use duration and subsequent UI requires further study in diverse populations. Understanding the temporal relationships between estrogen use and UI is important to practitioners counseling women with diverse reproductive histories regarding their risk of developing UI with condition-specific functional loss. Our investigation differs in several ways from previous work examining the association between UI and postmenopausal hormone therapy. We used standardized interviews in an ethnically diverse communitybased sample of women initially reporting no UI. Our sample is from an ongoing prospective observational study, allowing for the examination of temporal effects in disease causation for approximately a decade of follow-up, more than twice the length of follow-up reported by other studies. 6, 7 Our study design allowed us to estimate the temporal relationship between the duration of self-reported estrogen use at baseline and the development of UI at follow-up. Importantly, our data also include variables for the assessment of self-imposed functional loss resulting from lifestyle modifications related to UI, thus allowing for the assessment of disease severity associated with estrogen use. We recognize the exploratory nature of our analyses but took the opportunity afforded by the Epidemiologic Catchment Area (ECA) Program conducted by the National Institute of Mental Health to probe the association of selfreport of estrogen use at baseline and the incidence of UI after 10 years of follow-up.
The purpose of this article was to carefully examine the temporal relationships between self-reported postmenopausal estrogen use, UI, and condition-specific functional loss related to UI among an ethnically diverse community-based sample of postmenopausal women. We hypothesized that postmenopausal women with a longer duration of self-reported history of estrogen use would be more likely to report newly incident UI with condition-specific functional loss.
METHODS The Baltimore ECA program follow-up
The ECA Program conducted by the National Institute of Mental Health was a survey of psychiatric disorders in the general population between 1980 and 1984 at five universitybased sites in the United States. The Baltimore site of the ECA Program 8 probabilistically sampled 175,211 adult household residents in Eastern Baltimore in 1981, selecting 4,238 individuals for participation. Among the persons selected, 3,481 completed household interviews (82% of persons selected through random sampling). 9 In 1982, a second wave of interviews was conducted among 2,768 participants interviewed in 1981 (79.5%). Between 1993 and 1996, 1,920 (69.4%) participants who were interviewed in 1981 were interviewed again 10 (because most interviews were conducted in 1993, this wave is referred to as B1993[). Between 2004 and 2005, 1,071 participants interviewed in the previous wave (1993) (1994) (1995) (1996) were interviewed again (55.8%; because most interviews were conducted in 2004, this wave is referred to as B2004[). Data collected in 1993 and in 2004 are included in our analysis. UI was not assessed between 1981 and 1982; therefore, data from this wave are not included in our analysis. ECA data were obtained through highly structured interviews in a private place, usually the participant's home. At the baseline interview, the participants gave permission for future follow-up. The ECA study design and methods have been described in detail elsewhere. 11 In the current study, we took advantage of the existing ECA data set on postmenopausal women to explore the role of self-reported prolonged estrogen use in 1993 and incident UI in 2004, given the long duration of follow-up. The original protocol was approved by the Committee on Human Research of The Johns Hopkins University Institutional Review Board. 8 The present investigation was also approved by the Institutional Review Board at the University of Pennsylvania.
Urinary incontinence
The symptom of UI was assessed using the question BHave you ever had any difficulty in controlling your water, that is, losing your urine or having trouble getting to the bathroom on time?[ This conforms to the current definition of the symptom of UI provided by the International Continence Society. 12 Postmenopausal women reporting any uncontrolled urine loss within the 12 months before the interview were classified as having UI. Women denying uncontrolled urine loss within the 12 months before the interview were classified as continent.
UI and condition-specific functional loss
Four questions assessed condition-specific functional loss associated with UI. 13, 14 The participants were asked whether their UI resulted in Bavoiding social gatherings, visiting friends, and going to church[; Bavoiding traveling[; Bnot going shopping[; and Bavoiding physical activities.[ UI was the only condition in the ECA assessing condition-specific functional loss. The participants with a positive response to any of these questions were categorized as having condition-specific functional loss due to UI.
Estrogen use and reproductive history
The questionnaires contained detailed questions regarding previous hormone therapy including estrogen therapy and other questions about reproductive history. All responses were recorded in 1993. The questionnaire included questions that, after menopause, asked, BHave you ever taken estrogen pills for any reason?[ and BHow long did you take estrogen pills?[ The duration of estrogen use in 1993 was characterized into three broad categories (never used, used estrogen for less than 5 years, and used estrogen for 5 years or more) consistent with Hendrix et al. 5 Additional information in 1993 was obtained using standard questions about parity, menopausal duration, and type of menopause (surgical vs nonsurgical). 15 
Covariates
Educational attainment, self-identified ethnicity, and marital status were assessed in 1993 using structured questionnaires. Activities of daily living (ADLs) were assessed using standard survey items on using the toilet; knife or fork to cut up food; getting to bed by oneself; dressing and undressing; and taking a bath or shower. Instrumental activities of daily living (IADLs) were assessed through standard survey items on keeping track of money and bills, being able to get together with friends, preparing meals, cleaning the house, and using the telephone. Consistent with previous ECA reports, 16, 17 in 1993, individuals were characterized as having ADL or IADL impairment if they were unable to perform at least one activity without help. Participants were asked if they had ever had diabetes, heart trouble, arthritis, stroke, and cancer. A positive response to any of these conditions in 1993 was considered a medical comorbidity.
Smoking status was based on report of smoking within 7 days of the 1993 interview. Body mass index (BMI) was calculated as the weight in kilograms divided by the squared height in meters in 1993. Consistent with the definition for obesity, 18 BMI was dichotomized into equal to or greater than 30 kg/m 2 and less than 30 kg/m 2 .
Study sample
In all, 299 women responded Byes[ to the question BHave your menstrual cycles stopped permanently?[ in 1993. To examine the onset of UI directly, we excluded 103 postmenopausal women because they indicated that they had UI in the 1993 interview. These exclusionary criteria allowed us to begin the observation interval with a cohort of postmenopausal women who did not have UI. In addition, 29 women were excluded because they did not have complete data for other variables in our analysis, leaving a sample size of 167 for this analysis ( Table 1) .
Analytic strategy
The analytic plan proceeded in three phases. The first phase consisted of calculating the appropriate means and frequencies for each variable for participants with and without newly incident UI in 2004. Comparisons between groups of participants were made using W 2 or t tests as appropriate for categorical or continuous data. Bivariate associations between UI, estrogen use, and other important variables were examined. The second phase consisted of examining the age-adjusted relationship between the duration of estrogen use in years reported in 1993 and newly incident UI with and without condition-specific functional loss reported in 2004. Lastly, multivariable logistic regression models were developed to assess the relationship between the duration of estrogen use and newly incident UI. Multivariable models adjusted for age, education level, ethnicity, ADL and IADL impairment, chronic health conditions, body mass index, current smoking status, parity, and type of menopause. Data analysis was performed using SPSS version 12 (SPSS Inc., Chicago, IL).
RESULTS

Baseline characteristics
The mean (SD) age of the study sample was 57.1 (12.4) years. The self-identified ethnicity of participants was white (94; 56.3%), African American (64; 38.3%), American Indian (5; 3.0%), Asian (2; 1.2%), Hispanic (1; 0.6%), and Pacific Islander (1; 0.6%). Among the 167 postmenopausal women who did not report UI in 1993, 47 (28.1%) reported having UI within 1 year of 2004, and 31 (18.6%) reported having UI with condition-specific functional loss within 1 year of 2004. Of the 167 postmenopausal women, 46 (27.5%) reported ever using hormone therapy containing estrogen, and 14 (8.3%) reported using hormone therapy containing estrogen for 5 years or more in 1993.
Sociodemographic characteristics, functional status, health status, type of menopause, and duration of postmenopausal estrogen use were compared between women with and those without newly incident UI in 2004 (Table 1) . Postmenopausal women with and without newly incident UI were similar in BMI, current smoking status, parity, ethnicity, functional status, chronic medical conditions, and type of menopause. Postmenopausal women with newly incident UI were significantly older than were postmenopausal women without newly incident UI (P = 0.03). Postmenopausal women without newly incident UI trended toward a shorter duration of estrogen use, higher education level, and less impairment of IADLs; these differences approached but did not reach significance (all P Q 0.07).
Estrogen use and UI
In multivariate models, estrogen use for 5 years or more was significantly associated with newly incident UI compared with estrogen use for less than 5 years or no reported history of estrogen (adjusted relative odds [RO], 3.99; 95% CI, 1.21-13.10; Table 2 ). In multivariate models, estrogen use for 5 years or more was also significantly associated with newly incident UI with condition-specific functional loss compared with estrogen use for less than 5 years or no reported history of estrogen (adjusted RO, 3.97; 95% CI, 1.02-15.43). The final multivariate models controlled for potentially influential covariates including age, education level, ethnicity, ADL and IADL impairment, chronic health conditions, body mass index, current smoking status, parity, and type of menopause.
DISCUSSION
In our longitudinal study, community-dwelling postmenopausal women with a history of estrogen use for 5 years or more were more likely to report newly incident UI with condition-specific functional loss after 10 years of follow-up compared with women who reported estrogen use for less than 5 years or have no history of estrogen use. In routine clinical practice, women are asked to report their reproductive history including age at menopause and previous use of menopausal hormone therapy. Our results suggest that, among an ethnically diverse community-dwelling sample, self-report of previous estrogen use for 5 years or more at baseline may be associated with an increased risk of incident UI during the subsequent 10 years, especially when incontinence was associated with condition-specific functional loss. Our findings may be useful for counseling women interested in postmenopausal hormonal therapy.
Our study is consistent with previous research that showed that postmenopausal estrogen use is associated with worsening or incident UI. Our study augments previous work by studying a more ethnically diverse group of community-dwelling postmenopausal women. In a cohort of older postmenopausal women in the Women's Health Initiative, women randomized to receive estrogen with or without progestin had an increased risk of developing urge and stress UI after 1 year. 5 Another randomized controlled trial including older postmenopausal women with cardiac disease, the Heart Estrogen/progestin Replacement Study, also demonstrated an increased risk of developing stress and urge UI during 4 years of follow-up. 2 In addition, postmenopausal women in this trial with baseline UI were noted to have worsening symptoms during the same follow-up period. 3 Although our study did not specifically determine the dose of estrogen taken or whether progesterone was also used, our data similarly suggest that postmenopausal estrogen use is associated with UI and functional loss. In the Nurses' Health Study I, older postmenopausal female health professionals (aged 50-75 y) who reported taking postmenopausal hormones at baseline had a 34% to 68% increased risk of incident UI after 4 years compared with women who had never taken hormones irrespective of the type and route of hormone therapy, which is similar to our findings. 7 Comparable results were shown in younger postmenopausal women (aged 37-54 y) from the Nurses' Health Study II, in which there was a 39% increased risk of UI among current hormone therapy users after 2 years compared with nonusers of hormone therapy. 6 In addition, Grodstein et al 7 showed a significant trend toward decreasing risk of incident UI after participants self-reported stopping postmenopausal hormone therapy for 10 years compared with women who had never taken hormones, suggesting that the duration of discontinuation of estrogen may also play a role in the risk of UI. 19 Our findings join a growing body of literature that suggests that postmenopausal hormone therapy increases the risk of developing UI. However, the role of estrogen use for urinary symptoms is still unclear because of data from small clinical trials that suggest that there may be a benefit of local estrogen therapy on irritative voiding symptoms in women. 20 In addition, a study on postmenopausal women randomized to receive vaginal estrogen or placebo demonstrated that vaginal estrogen improves blood flow to the bladder neck and proximal urethra 21 but did not report a difference in UI symptoms. Nevertheless, available data support the hypothesis that oral estrogen worsens UI symptoms or increases the risk of developing UI.
Our study has several limitations that deserve comment. First, only recently have several validated questionnaires that measure type (urge, stress, or mixed) and severity of UI been published. 22<24 Because we were not able to use one of these instruments in 1993, our measure of UI is limited. For example, estrogen use has been found to be associated with incident stress incontinence. 5 However, using these instruments in 2004, when they were available, would have meant significant measurement changes and a loss in the ability to make individual longitudinal comparisons between 1993 and 2004. Furthermore, a crude examination of all types of UI together would probably reduce the chance of finding an association with incident UI and would have biased our results toward the null (ie, no effect of prolonged estrogen use on incident UI). In addition, the symptom of UI as measured by the Baltimore site of the ECA is consistent with the current definition of the International Continence Society. 12 Therefore, the symptom of UI in our study would be expected to be comparable with that in other published studies that also report UI based on this same definition. In addition, condition-specific functional loss serves as a marker of severity. 12 Second, examining incident UI in the preceding 12 months in 2004 may have missed women who developed UI during the intervening 10 years and were either successfully treated or had spontaneous remission of their UI resulting in misclassification bias. However, misclassification of some individuals with UI would probably lead to a conservative bias toward the null. Third, there is the potential for all sources of error associated with self-report interview data, including imperfect recall and response bias (eg, socially desirable responding). We attempted to mitigate these biases through limiting the recall of UI to the previous 12 months. In addition, the selfreport of UI among community-dwelling adults has been found to be reliable. 25 Fourth, although the initial study was drawn from a community sample, follow-up data consisted of women who could be found and be reinterviewed. However, studies based on the ECA follow-up data have shown little influence of baseline factors on loss to follow-up. 26 Fifth, we recognize that there is the potential role of chance because of the small number of participants in some subgroups. Our results, therefore, should be interpreted with caution, and we cannot make any broad conclusions or clinical recommendations based on our data. Finally, we confined our analysis to the self-report of use of oral estrogen only. We are not able to determine the specific risk associated with the combined use of estrogen and progesterone.
CONCLUSIONS
In summary, newly incident UI with condition-specific functional loss is associated with estrogen use for 5 years or more among a sample of community-dwelling postmenopausal women. Our study design is similar to how we obtain historical data clinically in women presenting for care. Most women are able to approximate the duration of use, and duration among those self-reporting use influences the risk of incident UI and the women's inability to engage in certain activities due to their UI. Future research is required to confirm a causal relationship between prolonged estrogen use and incident UI. In addition, more research is needed to understand further the biology of how hormone therapy affects bladder and urethral function to promote UI and to identify other therapies that will treat menopausal symptoms without the adverse effect of UI.
